Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITACa: Sequential Treatment Strategy in Metastatic Colorectal Cancer
NCT01878422Phase 3Completed
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Nov 2007
- Primary completion
- Mar 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab, cetuximab in metastatic colorectal cancer (mCRC), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Started Nov 2007; status: completed.
02
Drugs
bevacizumabcetuximab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01878422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01878422.